Summer Sale

50% off Premium Yearly

00days
00hrs
00mins
00secs
Stockchase Opinions

Michael SmedleyNeurochemNRM.TOBUYJul 28, 2004

There has been a general selloff of biotech stocks. Still believe in this company.
$22.85

Stock price when the opinion was issued

biotechnologypharmaceutical
It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.

You might be interested:

COMMENT
The name of the company was indistinct and this is the closest result in the data base. It is a biotech company focused on brain health. It acquired an AI company called Metro Mark. It is signing more and more deals with pharmaceutical companies for up-front and royalty payments.
SELL
He likes it, the only downside is that because the Japaneese market has risen 40% over the last year, it's a bit expensive right now. He suggests going to a different fund which is not so centered on the Japaneese market.
DON'T BUY
Looking at his relative performer chart, it's been an underperformer. Has negative money flow. In a very clear downtrend.
DON'T BUY
Feels it's a little pricey at these levels given where they are in the development of their program. Have some interesting programs.
BUY
Has been moving sideways which, for a biotech, is not too bad. The company has good backing. Should see considerable upside.
PAST TOP PICK
(A top pick Sept 9/03. Up100 %.) Still likes. The market opportunity is so big, would still buy at this price.
PAST TOP PICK
(A top pick Sept 9/03. Up 58%.) As a potential treatment for Alzheimer's. Good technology. Has some US financing which will get US investors interested.
TOP PICK
Into phase 3 trial. All cashed up. Will start to be getting attention.
BUY
Has a very strong range of products.
HOLD
Has gone up quite well and may stay level for awhile.
TOP PICK
Likes the managemnt. Big financial support.